Category: Cardiovascular Disease
February 14-20 is designated as Heart Failure Awareness Week. It is a great time to review our evolving treatment paradigm in the management of patients with heart failure, and to look ahead hopefully to the addition of new strategies under development.
One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine.
Lacopo Olivotto, MD, presented the results of the EXPLORER-HCM trial, which examined mavacamten as an alternative to surgical or catheter-based interventions to treat obstructive hypertrophic cardiomyopathy (HCM).
In addition to managing the enormous burden of COVID-19 infection and mortality, clinicians are also charged with how we can best provide ongoing regular care for non-COVID patients.
In a special report last week, the European Heart Journal spoke to cardiovascular disease (CVD) thought leaders across the globe to gather their insights on the impact of the COVID-19 pandemic on cardiovascular care.